We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.78%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.62B
AUM Growth
-$116M
(-6.7%)
Cap. Flow
+$444M
Cap. Flow
% of AUM
27.45%
Top 10 Holdings %
Top 10 Hldgs %
37.93%
Holding
108
New
37
Increased
28
Reduced
11
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burlington
BURL
|
+$54.3M |
| 2 |
Energizer
ENR
|
+$39.6M |
| 3 |
Amazon
AMZN
|
+$36.8M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$35.3M |
| 5 |
Avalo Therapeutics
AVTX
|
+$27.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Williams-Sonoma
WSM
|
+$32.8M |
| 2 |
AutoZone
AZO
|
+$29.4M |
| 3 |
Envista
NVST
|
+$25.1M |
| 4 |
Biogen
BIIB
|
+$21.2M |
| 5 |
Estee Lauder
EL
|
+$20.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.87% |
| 2 | Consumer Staples | 13.75% |
| 3 | Consumer Discretionary | 13.46% |
| 4 | Technology | 4.19% |
| 5 | Industrials | 2.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
United Therapeutics
UTHR
$23.1B
| – | – |
-128,000
| Closed | -$11.3M |
|
102
Vertex Pharmaceuticals
VRTX
$126B
| – | – |
-65,000
| Closed | -$14.2M |
|
|
103
Williams-Sonoma
WSM
$29.6B
| – | – |
-894,412
| Closed | -$32.8M |
|
|
ALIM
104
DELISTED
Alimera Sciences
ALIM
| – | – |
-340,000
| Closed | -$2.58M |
|
|
PRTK
105
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| – | – |
-2,268,000
| Closed | -$9.14M |
|
|
WBT
106
DELISTED
Welbilt, Inc.
WBT
| – | – |
-724,000
| Closed | -$11.3M |
|
|
DNKN
107
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| – | – |
-98,000
| Closed | -$7.4M |
|
|
MNK
108
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| – | – |
-2,678,000
| Closed | -$10.1M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Armistice Capital held 108 positions worth $1.62B, down 6.7% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Armistice Capital deployed $444M of net new capital in Q1 2020, opening 37 new positions and adding to 28 existing holdings. Its largest new stake was Burlington: 258,004 shares worth $40.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Biogen, an estimated $21.2M trimmed.
- Armistice Capital's largest Q1 2020 buy was Burlington: 258,004 shares worth $40.9M.
- Armistice Capital added most to Amazon in Q1 2020, an estimated $36.8M increase.
- Armistice Capital's biggest Q1 2020 reduction was Biogen, cutting an estimated $21.2M.
- Armistice Capital fully exited Williams-Sonoma in Q1 2020, selling an estimated $32.8M.
- Armistice Capital's ten largest holdings make up 38% of its $1.62B portfolio in Q1 2020.
- Armistice Capital opened 37 new positions and closed 29 in Q1 2020.
- Armistice Capital's portfolio value fell 6.7% quarter-over-quarter to $1.62B.
Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.